Stem Cells From Donated Fat Tissue for Mild to Moderate Alzheimer Disease
Tests the safety of donor fat-derived stem cells given by vein in Alzheimer disease.
Key facts
- Who runs it
- University Hospital, Toulouse
- Where
- Toulouse, FranceSee the site
- Trial code
- Registry title
- Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 9 people, planned
- Started
- 7 May 2026
- Expected to end
- 1 May 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- CellREADY® drug product IV dose of 50 millions
- CellREADY® drug product IV dose of 100 millions
- cerebral RMI
- PET scan
- Record updated
- 23 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 85 with mild to moderate Alzheimer disease and a positive amyloid biomarker.
- Age
- 50 to 85 years old
- Sex
- All sexes can join.
- Disease stage
- Mild to moderate Alzheimer disease (NIA-AA 2011 criteria), MMSE score between 14 and 26, CDR score of 1 or more.
- Earlier treatment
- Cannot join if you regularly use corticosteroids or other steroidal anti-inflammatory drugs. No PET scan in the previous year.
- Biomarker or test result
- A positive amyloid biomarker for Alzheimer disease.
Main reasons for not taking part
- Another brain disease that may cause dementia
- Cancer diagnosed within the last 5 years
- Autoimmune disease (psoriasis is allowed)
- More than 4 brain microbleeds or signs of earlier brain bleeding on MRI
- Pregnant or breastfeeding woman
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patient between 50 and 85 years old
- AD diagnosis according to NIA-AA 2011 criteria at a mild to moderate stage :; MMSE score between 14 and 26 (include) positive AD amyloid biomarker
- CDR (clinical dementia rating) score ≥ 1
- Patient with no absolute contraindications for PET or MRI scans
- Consent signed by the patient and study partner
- presence of primary caregiver
- Patient with social security coverage
Who cannot take part
- Presence of concomitant pathologies not permitting participation in the study
- Concurrent participation in other research that may influence the testing of the A3D study
- PET scan performed in the previous year (research context)
- Presence of > 4 brain microbleeds, a single area of superficial siderosis, or evidence of previous macrohaemorrhage assessed by brain MRI scan
- Regular use of corticosteroids or other steroidal anti-inflammatory drugs (e. g. prednisone)
- Brain disease (other than AD) that may cause dementia
- Carrier of a pacemaker, valve prosthesis or other internal magnetic or electronic system, history of neurosurgery or aneurysm surgery, presence of metal fragments in the eyes, brain or marrow, claustrophobia
- History of cancer diagnosed within the last 5 years
- Presence of an autoimmune disease (e. g. rheumatoid arthritis, systemic lupus erythematosus) with the exception of psoriasis
- Adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision For patients who will participate in the optional adipose puncture (only carried out in the Toulouse center): Antithrombotic treatment and xylocaine allergy are prohibited
- Pregnant or breastfeeding woman
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Where in France
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people
About the trial
What the trial wants to find out
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.
The 2 groups in the trial
- 50 millions AdMSC doseTreatment being tested
Allogeneic AdMSC (CellREADY® drug product), intravenous administration, dose of 50x106 or 100x106 AdMSC (from 3 to 6 patients, "50x106 AdMSC " group, group 1)
Treatment: CellREADY® drug product IV dose of 50 millions, cerebral RMI, and PET scan
- 100 millions AdMSc doseTreatment being tested
Allogeneic AdMSC (CellREADY® drug product), intravenous administration, dose of 50x106 or 100x106 AdMSC (from 3 to 6 patients, "100x106 AdMSC " group, group 2) if safety analysis of group 1 is correct.
Treatment: CellREADY® drug product IV dose of 100 millions, cerebral RMI, and PET scan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Allogeneic Intraveinous Injection of Adipose Tissue Derived-mesenchymal Stem Cells in Mild to Moderate Alzheimer Disease: a Phase I/II Trial
- Plain-language title
- Stem Cells From Donated Fat Tissue for Mild to Moderate Alzheimer DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07367815, who can take part
- Record updated
- 23 June 2026